Segment Information (Tables)

3 Months Ended

Jul. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands):

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Three Months Ended July 31, 2015	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	485	$	2,337	$	-	$	2,822
Direct cost of services		(634)		(1,588)		-		(2,222)
Sales and marketing costs		(332)		(577)		-		(909)
Other operating expenses		-		(933)		(880)		(1,813)
Stock- based compensation expense (1)		-		-		(775)		(775)
Segment loss	$	(481)	$	(761)	$	(1,655)	$	(2,897)

Three Months Ended July 31, 2014	Personalized Oncology Solutions (POS)		Translational Oncology Solutions (TOS)		Unallocated Corporate Overhead		Consolidated
Net revenue	$	341	$	1,571	$	-	$	1,912
Direct cost of services		(753)		(963)		-		(1,716)
Sales and marketing costs		(451)		(428)		-		(879)
Other operating expenses		-		(1,318)		(920)		(2,238)
Stock- based compensation expense (1)		-		-		(808)		(808)
Segment loss	$	(863)	$	(1,138)	$	(1,728)	$	(3,729)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.